Finally, Vuelta et al. recently reported their design of a new CRISPR/Cas9 short-deletion system that efficiently interrupts the BCR/ABL1 oncogene in murine and human cell lines and, for the first time, in primary leukemic stem cells Sca1+ from a CML mouse model and CD34+ from human CML patients [104]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.